Datavault AI expands healthcare blockchain licensing deal with DataMeds AI

Datavault AI broadened its licensing agreement with DataMeds AI to extend blockchain and data monetization tools into commercial healthcare, healthspan and wellness uses. The move is designed to support patient-controlled health data transactions across pharmacy, medical, laboratory and wearable settings as the companies work through related closing conditions.

Why it matters: - Datavault AI is pushing its data monetization and real-world asset tokenization tools deeper into healthcare, where patient data can drive new commercial models. - The expanded license could give DataMeds AI a broader technology base for pharmacy, medical, laboratory and wearable data flows. - The deal also points to a larger shift toward patient-controlled health data access and monetization.

What happened: - Datavault AI amended its definitive agreement with DataMeds AI to expand the PharmacyChain blockchain-related technology licensing relationship beyond pharmaceutical distribution. - The new scope covers all unencumbered commercial healthcare, healthspan and wellness applications of Datavault AI’s intellectual property. - The companies said the amendment was executed ahead of the remaining closing conditions to speed operational execution and technology access. - DataMeds AI’s EinsteinRX platform is the target environment for the expanded technology rollout.

The details: - Datavault AI will receive common shares representing about 19.9% of DataMeds AI common stock at closing of the previously disclosed related transactions, instead of preferred shares. - The change from preferred to common shares was made to optimize the transaction for tax purposes. - The share issuance still depends on closing conditions, including the acquisition of two QOLPOM intellectual property portfolios from EOS Technology Holdings and a controlling interest in Tollo Health LLC from HighBridge Advisors. - The value of the share issuance is expected to be categorized as revenue when the common shares are issued. - DataMeds AI was formerly Wellgistics Health, and its Nasdaq Capital Market ticker is MEDS. - DataMeds AI announced that its name change closed on July 21, 2026, and trading under MEDS began on July 22, 2026. - DataMeds AI is issuing 50 Dream Bowl Meme Coin tokens for each share owned as of the August 7, 2026 record date, subject to change at its sole discretion. - The behavioral healthcare patent portfolio being acquired was developed at La Frontera Arizona by the late Senator David T. Bradley and Dr. Dan Ranieri. - The portfolio covers medical and pharmaceutical logistics, IoT population health, and remote patient monitoring with AI-driven behavioral health insights and interventions. - DataMeds AI is acquiring the portfolio in concurrent transactions with EOS Technology Holdings and Scilex. - The companies said healthcare data represents about 30% of global data volume and is growing at an estimated 36% annually. - The companies also pointed to a global health and wellness market that exceeds $7 trillion. - Datavault AI is headquartered in Philadelphia. - DataMeds AI is headquartered in Tampa, Florida.

Between the lines: - The amendment suggests both companies want the licensing structure in place before every transaction piece is finalized. - Moving into patient-controlled data and tokenization could create a pathway for future monetization models beyond pharmacy distribution. - The healthcare pitch leans on a large and fast-growing data market, but the commercial outcome still depends on execution and regulatory fit.

What's next: - Datavault AI and DataMeds AI still need to satisfy the remaining closing conditions tied to the related transactions. - Those conditions include the EOS intellectual property acquisitions and the Tollo Health controlling-interest deal. - If the deals close, Datavault AI’s equity stake and the broader healthcare licensing relationship should move into active implementation. - More information is available through B2i Digital’s Featured Companies page.